What is known and objective The FDA has provided recommendations for aripiprazole use
in CYP2D6 poor metabolizers (PMs); however, PMs make up< 1% of the Asian population …

Background Plasmodium vivax malaria requires a 2-week course of primaquine (PQ) for
radical cure. Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 …

Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of up to 20% of small-
molecule drugs and therefore, may impact the safety and efficacy of medicines in broad …

Background Primaquine (PQ) actively clears mature Plasmodium falciparum gametocytes
but in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals can cause …

Aim: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity.
Patients & methods: Healthy pediatric subjects (n= 189) were phenotyped using …

In toxicogenetics, an integrative approach including the prediction of phenotype based on
post-mortem genotyping of drug-metabolising enzymes might help explain the cause of …

Tamoxifen is an endocrine treatment for hormone receptor positive breast cancer. The
effectiveness of tamoxifen may be compromised in patients with metabolic resistance, who …

Background There are few and conflicting data on the role of cytochrome P450 2D6
(CYP2D6) polymorphisms in relation to risperidone adverse events (AEs) in children. This …

Background CYP2D6 plays a crucial role in drug metabolism of several drugs. It is known to
be highly polymorphic with enzymatic activity ranging from poor to ultrarapid metabolic rates …

Cytochrome P450 (CYP) 2D6, a major contributor to the metabolism and bioactivation of
many clinically used drugs, is encoded by a complex, highly polymorphic gene locus. To aid …